NATCO Pharma moves higher on getting USFDA's tentative approval for Erdafitinib Tablets

03 Feb 2026 Evaluate

NATCO Pharma is currently trading at Rs. 852.55, up by 29.05 points or 3.53% from its previous closing of Rs. 823.50 on the BSE.

The scrip opened at Rs. 880.05 and has touched a high and low of Rs. 880.05 and Rs. 845.50 respectively. So far 34316 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1340.45 on 07-Feb-2025 and a 52 week low of Rs. 660.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 880.05 and Rs. 808.00 respectively. The current market cap of the company is Rs. 15260.16 crore.

The promoters holding in the company stood at 49.48%, while Institutions and Non-Institutions held 20.54% and 29.97% respectively.

NATCO Pharma has received tentative approval from U.S. Food and Drug Administration (USFDA) for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa by Janssen Biotech Inc. NATCO’s Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy. 

Erdafitinib tablets had estimated sales of around $60 million in the U.S. for 12 months ending September 2025 as per industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

984.65 13.25 (1.36%)
27-Feb-2026 15:34 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1746.00
Dr. Reddys Lab 1289.90
Cipla 1340.00
Zydus Lifesciences 922.85
Lupin 2301.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×